Home > Healthcare > Medical Devices > Diagnostic Devices > Primary Care POC Diagnostics Market

Primary Care POC Diagnostics Market Trends

Report ID: GMI7895
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Primary Care POC Diagnostics Market Trends

The increasing technological advancements in the primary care POC diagnostics market is projected to augment significant industry expansion. Current trend in the industry is strongly persuaded towards smart devices equipped with mobile healthcare that will significantly accelerate growth of remote patient monitoring and management. Wide range of mobile healthcare technologies have been developed, of which cell phone-based point of care technologies has become the most prominent technology.

In addition, real time PCR has significantly expanded diagnostic capability through its capability of amplification and pathogen DNA identification technology
Thus, high accuracy levels, more reliability as well as rapid and precise results delivered by numerous molecular tests has stimulated its demand in infectious disease management, thereby escalating the market growth.
Moreover, growing government initiatives towards acute cases including road traffic accidents, developing healthcare infrastructure, and patient support programs will spur the adoption of primary care POC diagnostics, thus propelling market revenue growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global primary care POC diagnostics industry was valued at USD 18.3 billion in 2023 and is estimated to reach USD 33.6 billion by 2032, owing to the increasing incidence of infectious diseases and chronic conditions including cardiovascular diseases.

The glucose monitoring segment garnered USD 4.5 billion revenue size in the year 2023, driven by the increasing adoption of portable, high convenience, and cost-effectiveness as well as rapid primary POC glucose tests.

U.S. primary care POC diagnostics market accounted for USD 6.9 billion revenue size in 2023 and is predicted to witness substantial growth through 2032, attributed to the increasing government initiatives towards chronic and infectious diseases.

Abbott Laboratories., Sysmex Corporation., ACON Laboratories, Inc., Siemens Healthineers AG., Becton, Dickinson, and Company, Nova Biomedical., BioMerieux SA, Bio-Rad Laboratories, Inc, HemoCue AB (Danaher Corporation)., Dexcom, Inc., HemoCue AB (Danaher Corporation) and Dragerwerk Ag & Co.